BGT-226 | Interleukin Related interleukin-related.com

Product Name :
BGT-226

Search keywords :
BGT226

drugId :
null

Target Vo:
Mammalian target of Rapamycin (mTORC1)

Target Vo Short Name :
mTORC1

Moa_Name:
Mammalian target of Rapamycin (mTORC1) inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Novartis Pharma Ag

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Hamartoma Syndrome, Multiple

Termination Status :
Phase 2 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
EpCAM Rabbit mAb Purity & Documentation
nNOS Rabbit mAb In stock
DDIT3 Antibody: DDIT3 Antibody is an unconjugated, approximately 19 kDa, rabbit-derived, anti-DDIT3 polyclonal antibody. DDIT3 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: dog, pig, cow, horse, rabbit, sheep background without labeling.

Author: Interleukin Related

Related Posts